Cargando…

Cost of digital technologies and family-observed DOT for a shorter MDR-TB regimen: a modelling study in Ethiopia, India and Uganda

BACKGROUND: In 2017, the WHO recommended the use of digital technologies, such as medication monitors and video observed treatment (VOT), for directly observed treatment (DOT) of drug-susceptible TB. The WHO’s 2020 guidelines extended these recommendations to multidrug-resistant tuberculosis (MDR-TB...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosu, Laura, Madan, Jason, Bronson, Gay, Nidoi, Jasper, Tefera, Mamo G., Malaisamy, Muniyandi, Squire, Bertel S., Worrall, Eve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657602/
https://www.ncbi.nlm.nih.gov/pubmed/37980524
http://dx.doi.org/10.1186/s12913-023-10295-z
_version_ 1785148180267008000
author Rosu, Laura
Madan, Jason
Bronson, Gay
Nidoi, Jasper
Tefera, Mamo G.
Malaisamy, Muniyandi
Squire, Bertel S.
Worrall, Eve
author_facet Rosu, Laura
Madan, Jason
Bronson, Gay
Nidoi, Jasper
Tefera, Mamo G.
Malaisamy, Muniyandi
Squire, Bertel S.
Worrall, Eve
author_sort Rosu, Laura
collection PubMed
description BACKGROUND: In 2017, the WHO recommended the use of digital technologies, such as medication monitors and video observed treatment (VOT), for directly observed treatment (DOT) of drug-susceptible TB. The WHO’s 2020 guidelines extended these recommendations to multidrug-resistant tuberculosis (MDR-TB), based on low evidence. The impact of COVID on health systems and patients underscored the need to use digital technologies in the management of MDR-TB. METHODS: A decision-tree model was developed to explore the costs of several potential DOT alternatives: VOT, 99DOTS (Directly-observed Treatment, Short-course) and family-observed DOT. Assuming a 9-month, all-oral regimen (as evaluated within the STREAM trial), we constructed base-case cost models for the standard-of-care DOTs in Ethiopia, India, and Uganda, as well as for the three alternative DOT approaches. The models were populated with STREAM Stage 2 clinical trial outcome and cost data, supplemented with market prices data for the digital DOT strategies. Sensitivity analyses were conducted on key parameters. RESULTS: Modelling suggested that the standard-of-care DOT approach is the most expensive DOT strategy from a societal perspective in all three countries evaluated (Ethiopia, India, Uganda), with considerable direct- and indirect-costs incurred by patients. The second most expensive DOT approach is VOT, with high health-system costs, largely caused by up-front technology expenditure. Each of VOT, 99DOTS and family-observed DOT would reduce by more than 90% patients’ direct and indirect costs compared to standard of care DOT. Results were robust to the sensitivity analyses. CONCLUSIONS: While data on the costs and efficacy of alternative DOT approaches in the context of shorter MDR-TB treatment is limited, our modelling suggests alternative DOT approaches can significantly reduce patient costs in all three countries. Health system costs are higher for VOT and lower for 99DOTS and family-observed therapy when compared to standard of care DOT, as low smartphone penetration and internet availability requires the VOT health system to fund the cost of making them available to patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-10295-z.
format Online
Article
Text
id pubmed-10657602
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106576022023-11-18 Cost of digital technologies and family-observed DOT for a shorter MDR-TB regimen: a modelling study in Ethiopia, India and Uganda Rosu, Laura Madan, Jason Bronson, Gay Nidoi, Jasper Tefera, Mamo G. Malaisamy, Muniyandi Squire, Bertel S. Worrall, Eve BMC Health Serv Res Research BACKGROUND: In 2017, the WHO recommended the use of digital technologies, such as medication monitors and video observed treatment (VOT), for directly observed treatment (DOT) of drug-susceptible TB. The WHO’s 2020 guidelines extended these recommendations to multidrug-resistant tuberculosis (MDR-TB), based on low evidence. The impact of COVID on health systems and patients underscored the need to use digital technologies in the management of MDR-TB. METHODS: A decision-tree model was developed to explore the costs of several potential DOT alternatives: VOT, 99DOTS (Directly-observed Treatment, Short-course) and family-observed DOT. Assuming a 9-month, all-oral regimen (as evaluated within the STREAM trial), we constructed base-case cost models for the standard-of-care DOTs in Ethiopia, India, and Uganda, as well as for the three alternative DOT approaches. The models were populated with STREAM Stage 2 clinical trial outcome and cost data, supplemented with market prices data for the digital DOT strategies. Sensitivity analyses were conducted on key parameters. RESULTS: Modelling suggested that the standard-of-care DOT approach is the most expensive DOT strategy from a societal perspective in all three countries evaluated (Ethiopia, India, Uganda), with considerable direct- and indirect-costs incurred by patients. The second most expensive DOT approach is VOT, with high health-system costs, largely caused by up-front technology expenditure. Each of VOT, 99DOTS and family-observed DOT would reduce by more than 90% patients’ direct and indirect costs compared to standard of care DOT. Results were robust to the sensitivity analyses. CONCLUSIONS: While data on the costs and efficacy of alternative DOT approaches in the context of shorter MDR-TB treatment is limited, our modelling suggests alternative DOT approaches can significantly reduce patient costs in all three countries. Health system costs are higher for VOT and lower for 99DOTS and family-observed therapy when compared to standard of care DOT, as low smartphone penetration and internet availability requires the VOT health system to fund the cost of making them available to patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-10295-z. BioMed Central 2023-11-18 /pmc/articles/PMC10657602/ /pubmed/37980524 http://dx.doi.org/10.1186/s12913-023-10295-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Rosu, Laura
Madan, Jason
Bronson, Gay
Nidoi, Jasper
Tefera, Mamo G.
Malaisamy, Muniyandi
Squire, Bertel S.
Worrall, Eve
Cost of digital technologies and family-observed DOT for a shorter MDR-TB regimen: a modelling study in Ethiopia, India and Uganda
title Cost of digital technologies and family-observed DOT for a shorter MDR-TB regimen: a modelling study in Ethiopia, India and Uganda
title_full Cost of digital technologies and family-observed DOT for a shorter MDR-TB regimen: a modelling study in Ethiopia, India and Uganda
title_fullStr Cost of digital technologies and family-observed DOT for a shorter MDR-TB regimen: a modelling study in Ethiopia, India and Uganda
title_full_unstemmed Cost of digital technologies and family-observed DOT for a shorter MDR-TB regimen: a modelling study in Ethiopia, India and Uganda
title_short Cost of digital technologies and family-observed DOT for a shorter MDR-TB regimen: a modelling study in Ethiopia, India and Uganda
title_sort cost of digital technologies and family-observed dot for a shorter mdr-tb regimen: a modelling study in ethiopia, india and uganda
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657602/
https://www.ncbi.nlm.nih.gov/pubmed/37980524
http://dx.doi.org/10.1186/s12913-023-10295-z
work_keys_str_mv AT rosulaura costofdigitaltechnologiesandfamilyobserveddotforashortermdrtbregimenamodellingstudyinethiopiaindiaanduganda
AT madanjason costofdigitaltechnologiesandfamilyobserveddotforashortermdrtbregimenamodellingstudyinethiopiaindiaanduganda
AT bronsongay costofdigitaltechnologiesandfamilyobserveddotforashortermdrtbregimenamodellingstudyinethiopiaindiaanduganda
AT nidoijasper costofdigitaltechnologiesandfamilyobserveddotforashortermdrtbregimenamodellingstudyinethiopiaindiaanduganda
AT teferamamog costofdigitaltechnologiesandfamilyobserveddotforashortermdrtbregimenamodellingstudyinethiopiaindiaanduganda
AT malaisamymuniyandi costofdigitaltechnologiesandfamilyobserveddotforashortermdrtbregimenamodellingstudyinethiopiaindiaanduganda
AT squirebertels costofdigitaltechnologiesandfamilyobserveddotforashortermdrtbregimenamodellingstudyinethiopiaindiaanduganda
AT worralleve costofdigitaltechnologiesandfamilyobserveddotforashortermdrtbregimenamodellingstudyinethiopiaindiaanduganda